文献速递传染病防控与疫情报告免疫规划妇幼与学校卫生

荷兰2012至2024年百日咳监测与疫苗效果:2023-2024年异常激增

Surveillance and vaccine effectiveness of pertussis, the Netherlands, 2012 to 2024, with an unprecedented surge in 2023 and 2024.
PubMed 文献 · Euro Surveill · 2026-01-01

荷兰2023-24年百日咳激增,2024年报告18,208例(102/10万)。婴儿0-5月龄发病率最高(573/10万)。孕妇疫苗效果对0-2月龄婴儿为91%,婴儿基础免疫1岁时效果98%。建议提升疫苗接种率。

要点

  • 2024年百日咳报告率102/10万,0-5月龄婴儿发病率最高。
  • 2020-24年孕妇接种对0-2月龄婴儿疫苗效果91%。
  • 婴儿基础免疫1岁时效果98%,9岁时降至71%。

核心结论

  • 2023-24年荷兰百日咳发病率创历史新高,低人群免疫可能为主因。
  • 孕妇和婴儿疫苗效果均高,应优先提升接种率。

研究设计与样本

  • 回顾性研究,使用2012-2024年百日咳报告数据。
  • 采用筛查法估算婴儿和孕妇疫苗效果。

主要发现

  • 2021年报告数降至79例(发病率<0.01/10万),2024年升至18,208例(102/10万)。
  • 2024年0-5月龄婴儿报告发病率和住院率分别为573/10万和304/10万。
  • 2023-24年报告10例死亡(6例婴儿,4例≥60岁)。
  • 2024年0-2月龄报告婴儿中83%的母亲未接种疫苗。

关键数值与推荐

  • 2020-24年孕妇疫苗效果对0-2月龄婴儿为91%。
  • 2012-24年婴儿基础免疫效果:1岁98%,3岁92%,5岁加强后92%,9岁71%。

临床怎么用

  • 加强孕妇百日咳疫苗接种以保护0-2月龄婴儿。
  • 维持婴儿基础免疫高接种率,关注9岁时疫苗效果下降。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUNDA surge in pertussis occurred in the Netherlands in 2023-24. Infant vaccination uptake decreased from 95% in 2011 to ca 86% in 2024. Maternal vaccination was introduced in 2019, with uptake ca 70%.AIMTo describe pertussis epidemiological trends in the Netherlands.METHODSWe conducted a retrospective study using pertussis notification data from 2012 to 2024 and estimated infant and maternal vaccine effectiveness (VE) with the screening method.RESULTSDuring the COVID-19 pandemic, pertussis notifications dropped from ca 6,000 in 2013-19 to 79 in 2021 (incidence ca 35 to < 0.01/100,000 population). Notifications surged from May 2023, peaking in March 2024, resulting in 18,208 notifications in 2024 (102/100,000). Notifications and hospitalisations in 2024 were highest among infants aged 0-5 months (573 and 304/100,000) followed by infants aged 6-11 months (446 and 92/100,000). Annually, 0-2 deaths were reported; in 2023-24, 10 deaths were reported (6 infants, 4 ≥ 60-year-olds). In 2024, 83% of mothers of notified infants aged 0-2 months were unvaccinated. In 2020-24, maternal VE against pertussis in infants aged 0-2 months was 91%. In 2012-24 primary series VE was 98% at age 1, 92% at age 3, 92% post-booster at age 5, and 71% at age 9 years.CONCLUSIONLow population immunity after 2 years of reduced circulation likely contributed to the highest pertussis incidence ever recorded in the Netherlands, posing a particular threat to unprotected infants. Maternal and infant VE are high, underscoring the public health priority of enhancing vaccination uptake.

来源:Euro Surveill,查看原文。版权归原作者所有。

引用

  1. van Roon A, van Meijeren D, de Gier B, et al. Surveillance and vaccine effectiveness of pertussis, the Netherlands, 2012 to 2024, with an unprecedented surge in 2023 and 2024. Euro Surveill. 2026. PMID: 42141889. doi:10.2807/1560-7917.ES.2026.31.15.2500919

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。